These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 11362464

  • 21. Nelfinavir (Viracept) price increase 4.6 percent.
    AIDS Treat News; 1998 Oct 16; (No 305):3-4. PubMed ID: 11365867
    [Abstract] [Full Text] [Related]

  • 22. Protease inhibitors: resistance, resistance, resistance.
    Gilden D, Falkenberg J, Torres G.
    GMHC Treat Issues; 1997 Feb 16; 11(2):5-10. PubMed ID: 11364108
    [Abstract] [Full Text] [Related]

  • 23. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S, Larrú B, Maria Bellón J, Resino R, de José MI, Navarro M, Léon JA, Ramos JT, Mellado MJ, Muñoz-Fernández MA.
    BMC Infect Dis; 2006 Jul 11; 6():107. PubMed ID: 16834769
    [Abstract] [Full Text] [Related]

  • 24. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr 11; 10(2):3-4. PubMed ID: 11365434
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Nelfinavir combination therapy: ten-month report.
    AIDS Treat News; 1997 Apr 18; (No 269):3. PubMed ID: 11364253
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb 18; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 34. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C, Burri M, Shen Y, Rode R, Nadal D, Pediatric Infectious Disease Group of Switzerland, Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Pediatr Infect Dis J; 2008 May 18; 27(5):431-7. PubMed ID: 18382386
    [Abstract] [Full Text] [Related]

  • 35. Update on HIV protease inhibitors.
    Vella S.
    AIDS Clin Care; 1995 Oct 18; 7(10):79-82, 88. PubMed ID: 11362832
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 18; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
    Prescott LM.
    Body Posit; 1998 Dec 18; 11(12):11-2. PubMed ID: 11366134
    [Abstract] [Full Text] [Related]

  • 38. Other options: clinical trials.
    Treat Rev; 1998 Dec 18; (No 28):13-4. PubMed ID: 11365420
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.